Patents Assigned to Intra-Cellular Therapies, Inc.
  • ORGANIC COMPOUNDS
    Publication number: 20230339951
    Abstract: The invention relates to pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)-butan-1-one, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) pathway and/or the dopamine D2 receptor pathway, and methods of treating conditions of the central nervous system therewith.
    Type: Application
    Filed: June 1, 2023
    Publication date: October 26, 2023
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng LI, Qiang ZHANG, Robert DAVIS, Lawrence P. WENNOGLE
  • NOVEL SALTS, CRYSTALS, AND CO-CRYSTALS
    Publication number: 20230312573
    Abstract: The disclosure provides salts and crystal forms of a substituted heterocycle fused gamma-carboline, the manufacture thereof, pharmaceutical compositions thereof, and use thereof, e.g., in the treatment of diseases or abnormal conditions involving or mediated by the 5-HT2A receptor, serotonin transporter (SERT), and/or dopamine D1/D2 receptor signaling pathways.
    Type: Application
    Filed: September 3, 2021
    Publication date: October 5, 2023
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventor: Peng LI
  • Organic compounds
    Patent number: 11773095
    Abstract: The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Grant
    Filed: July 19, 2022
    Date of Patent: October 3, 2023
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Hailin Zheng, Robert Davis, Sharon Mates, Kimberly Vanover, Gretchen Snyder
  • TRANSMUCOSAL METHODS FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS
    Publication number: 20230301995
    Abstract: The disclosure provides new transmucosal and subcutaneous pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d2-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d4-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.
    Type: Application
    Filed: May 17, 2023
    Publication date: September 28, 2023
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng LI, Wei YAO, Robert DAVIS
  • Uses
    Patent number: 11759465
    Abstract: The disclosure provides methods, treatments and materials for enhancing the effect of an adenosine A2 receptor agonist in the treatment, mitigation or prophylaxis of a disease or condition characterized by inotropic and/or lusitropic dysfunction, and/or enhancing adenosine A2 receptor function in the treatment, mitigation or prophylaxis of a disease or condition characterized by impaired adenosine A2 receptor function, comprising administration of an effective amount of a PDE1 inhibitor to a patient in need thereof, for example a patient suffering from heart failure.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: September 19, 2023
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: David Kass, Toru Hashimoto, Lawrence P. Wennogle, Joseph Hendrick, Robert Davis
  • 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3?4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders
    Patent number: 11753419
    Abstract: The invention relates to a particular substituted heterocycle fused gamma carboline, the compound of Formula I, and new methods and uses pertaining thereto, and pharmaceutical compositions thereof, such as methods of use in the treatment of diseases involving the 5-HT receptor, the serotonin transporter (SERT), and/or pathways involving dopamine D2 receptor signaling, sodium channel activity, and/or norepinephrine transporter activity.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: September 12, 2023
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Robert E Davis, Kimberly Vanover
  • ORGANIC COMPOUNDS
    Publication number: 20230271962
    Abstract: The invention relates to pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)-butan-1-ol, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) pathway and/or the dopamine D2 receptor pathway, and methods of treating conditions of the central nervous system therewith.
    Type: Application
    Filed: May 9, 2023
    Publication date: August 31, 2023
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng LI, Qiang ZHANG, Robert DAVIS, Lawrence P. WENNOGLE
  • Organic compounds
    Patent number: 11723909
    Abstract: The invention relates to particular substituted deuterated heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.
    Type: Grant
    Filed: July 19, 2021
    Date of Patent: August 15, 2023
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Wei Yao, Peng Li
  • Pharmaceutical capsule compositions comprising lumateperone mono-tosylate
    Patent number: 11690842
    Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.
    Type: Grant
    Filed: May 27, 2021
    Date of Patent: July 4, 2023
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Robert Davis
  • ORGANIC COMPOUNDS
    Publication number: 20230203037
    Abstract: This invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.
    Type: Application
    Filed: December 16, 2022
    Publication date: June 29, 2023
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon MATES, Peng LI, Lawrence P. WENNOGLE, Robert DAVIS
  • Pharmaceutical compositions comprising 4-(6Br,10aS)-3-methyl-2, 3, 6b, 9, 10, 10a-hexahydro-1H, 7H-pyrido[3?, 4?, 5] pyrolo[1,2,3-de] quinoxalin-8YL)-1-(4-fluorophenyl)-butane-1-one and methods of treating conditions of the central nervous system
    Patent number: 11680065
    Abstract: The invention relates to pharmaceutical compositions comprising, compounds of Formula Q: wherein W is —N(H)—, or —N(CH3)—, and Y is —C(?O)— or —O—, in free base or pharmaceutically acceptable salt form, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) pathway and/or the dopamine D2 receptor pathway, and methods of treating conditions of the central nervous system therewith.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: June 20, 2023
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Qiang Zhang, Robert Davis, Lawrence P. Wennogle
  • ORGANIC COMPOUNDS
    Publication number: 20230181576
    Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Application
    Filed: September 9, 2020
    Publication date: June 15, 2023
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Wei YAO, Peng LI, Robert DAVIS, Sharon MATES, Kimberly VANOVER, Gretchen SNYDER
  • FREE BASE CRYSTALS
    Publication number: 20230174543
    Abstract: The present invention relates to crystals of (6aR, 9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-?]pyrazolo[4,3-e]pyrazolo[4,3-e]pyrimidin-4(2H)-one, and methods of making and using such crystals.
    Type: Application
    Filed: May 6, 2021
    Publication date: June 8, 2023
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventor: Peng LI
  • Organic compounds
    Patent number: 11560382
    Abstract: This invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: January 24, 2023
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon Mates, Peng Li, Lawrence P. Wennogle, Robert Davis
  • Uses
    Patent number: 11504372
    Abstract: The subject matter generally relates to methods of treatment and/or prophylaxis of CNS diseases, disorders, and/or injuries. In one aspect, the subject matter relates to inhibitors of phosphodiesterase 1 (PDE1) as neuroprotective agents and/or neural regenerative agents. In a further aspect, the subject matter relates to individuals that are at risk for the development of CNS disease or disorder.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: November 22, 2022
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventor: Lawrence P. Wennogle
  • Organic compounds
    Patent number: 11491150
    Abstract: The disclosure relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., diabetes mellitus, chronic kidney disease, acute kidney failure, and reduction of blood glucose levels.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: November 8, 2022
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Youyi Peng, Lawrence P. Wennogle, Qiang Zhang
  • SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS
    Publication number: 20220332716
    Abstract: The present invention provides methods for the preparation of substituted heterocycle fused gamma-carbolines, intermediates useful in producing them and methods for producing such intermediates and such heterocycl fused gamma-carbolines.
    Type: Application
    Filed: June 24, 2022
    Publication date: October 20, 2022
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: John Charles TOMESCH, Peng LI, Wei YAO, Qiang ZHANG, James David BEARD, Andrew S. THOMPSON, Hua CHENG, Lawrence P. WENNOGLE
  • PDE1 inhibitors for ophthalmic disorders
    Patent number: 11464781
    Abstract: Compounds that inhibit phosphodiesterase 1 (PDE1) are useful to treat glaucoma or elevated intraocular pressure. The PDE1 inhibitors may be administered as monotherapy or in combination with additional intraocular-pressure lowering agents. In addition, the invention provides ophthalmic compositions comprising PDE 1 inhibitors and optionally one or more additional intraocular pressure-lowering agents. Topical and systemic therapy may be used.
    Type: Grant
    Filed: February 24, 2010
    Date of Patent: October 11, 2022
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Robert Davis, Allen Fienberg
  • Substituted heterocycle fused gamma-carbolines synthesis
    Patent number: 11453670
    Abstract: The present invention provides improved methods for the preparation of substituted heterocycle fused gamma-carbolines, intermediates useful in producing them and methods for producing such intermediates and such heterocycle fused gamma-carbolines.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: September 27, 2022
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Qiang Zhang
  • Salts and crystals
    Patent number: 11440911
    Abstract: The disclosure provides new, stable, pharmaceutically acceptable hydrochloride salt forms of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, together with methods of making and using them, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: September 13, 2022
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Lawrence P. Wennogle, Peng Li, Edwin Aret